Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?-Reference-Cited by-同舟云学术

Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?

Published:2024-04 Issue: Volume:236 Page:236-239
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Vassart Julie,Didembourg Marie,Morimont Laure,Brisbois Clotilde,Jamart Laurent,Lebreton Aurélien,Mullier François,Donis Nathalie,Favresse Julien,Dogné Jean-Michel,Douxfils Jonathan

Funder

Université de Namur

Publisher

Elsevier BV

Reference10 articles.

1. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study;Piccini;Lancet,2022

2. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?;Robert;Pharmacol. Res.,2009

3. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?;Spronk;Thromb. Haemost.,2009

4. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor;Perera;Clin. Transl. Sci.,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

2. Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation;Expert Opinion on Drug Metabolism & Toxicology;2024-09-02

3. The current landscape of factor XI inhibitors;Thrombosis Update;2024-06